Novartis

Pharma

Lilly-InnoCare, Elevar, China's 5-year plan—Fierce Pharma Asia

Lilly and InnoCare inked a potential $3.35 billion deal. The FDA approved a novel cancer drug in a first for Korea. China set ambitious five-year plan.

Angus Liu Sep 25, 2026 9:38am

European pharmas sound alarm over lagging innovation

Sep 22, 2026 11:29am

Legend Biotech names Novartis veteran Ingrid Zhang as new CEO

Sep 16, 2026 10:12am

FDA approves first radioligand equivalent

Sep 15, 2026 8:38am

Novartis investor calls for board overhaul after costly setbacks

Sep 10, 2026 10:26am

Roche, GSK, Novartis, MFN, Akeso and more—Fierce Pharma Asia

Sep 4, 2026 8:52am